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Introduction. Dopamine-replacement medications may improve mobility while not improving responses to postural challenges
and could therefore increase fall risk. The purpose of this study was to measure reactive postural responses and gait-related
mobility of patients with PD during ON and OFF medication conditions. Methods. Reactive postural responses to the Pull
Test and performance of the Functional Gait Assessment (FGA) were recorded from 15 persons with PD during ON and OFF
medication conditions. Results. Persons with PD demonstrated no signiﬁcant diﬀerence in the reactive postural responses between
medication conditions but demonstrated signiﬁcantly better performance on the FGA when ON medications compared to OFF.
Discussion/Conclusion. Dopamine-replacement medications alone may improve gait-related mobility without improvements in
reactive postural responses and therefore could result in iatrogenic increases in fall risk. Rehabilitation providers should be aware
o ft h es i d ee ﬀects and limitations of medication treatment and implement interventions to improve postural responses.
1.Introduction
Parkinson disease (PD) is the most prominent of the hypo-
kinetic disorders [1, 2]. The cardinal features of PD are tre-
mor at rest, rigidity, hypokinesia, and postural instability
[3, 4]. Postural instability and falls constitute major reasons
for the serious complications in advanced PD [5, 6]. Falls
are associated with high morbidity, mortality [7], and
diminishedqualityoflife[8,9].Currentestimatesreportthat
up to 70% of those with PD fall each year, and 13% fall more
than once a week [5, 10].
The majority of persons with PD will be treated with
dopamine-replacementmedicationsandthebeneﬁtsofthese
medications on overall motor function and mobility are
well established [11, 12]. However, limitations of dopamine
replacement do exist. One of these limitations is the minimal
eﬀect of dopamine-replacement medications on postural
instability [13–15]. Coupling the beneﬁts of increased gait-
related mobility and the limitation that postural instability
is dopamine-resistant raises the possibility that fall risk may
increase through increased exposure to postural challenges.
With such a high incidence of falls and the apparent dop-
amine-resistantnatureofposturalinstability,anunderstand-
ing of the extent and character of how postural responses
and gait-related mobility respond to dopamine-replacement
medication is critical for optimal rehabilitative treatment.
Despite the apparent paradox between dopamine replac-
ment eﬀects on postural responses and gait-related mobility,
to our knowledge, no studies have systematically examined
these variables in detail. As an intial step in exploring this
postural response—mobility paradox, we sought to examine
the potential diﬀerential eﬀect of dopamine replacement
on postural instability and gait-related mobility. This study
had the following objectives: (1) quantitatively measure
the kinematic characteristics of reactive postural responses
and gait-related mobility in persons with PD during both
ON and OFF medication conditions and (2) examine the
speciﬁc components of gait-related mobility (e.g., on level
surface, speed, with change in head position, with pivots,
over obstacle, with narrow support, with eyes closed, back-
wards, and steps) that were dopamine-responsive. Based on
previous research [13, 14], we hypothesized that dopamine2 Parkinson’s Disease
replacement would not improve the kinematics of reac-
tive postural responses. In contrast, we hypothesized that
dopamine replacement would improve performance on gait-
related mobility, but only through the improvement of spe-
ciﬁc components of the Functional Gait Assessment (FGA).
2. Methods
2.1. Selection of Participants. Potential participants were
a sample of convenience recruited through referral from
local neurologists or response to advertisement in a PD
support group newsletter. The inclusion criteria were a
medically conﬁrmed diagnosis of idiopathic PD, a stable
and neurologist-optimized medication regime that included
dopamine replacement as well as other anti-Parkinson med-
ications, and the ability to independently ambulate in the
community with or without an assistive device. PD par-
ticipants were excluded from the study if they had a
history of medical conditions (orthopedic, cardiovascular, or
otherwise) that would limit their ability to participate in the
study procedures.
2.2. Measures. The most common research paradigms to
examine medication eﬀects on postural instability utilize
sliding or rotating force plates that induce postural sway.
While having high degrees of internal validity for research
purposes, these paradigms lack external and ecologic validity
because the ﬂoor sliding or rotating underneath a person is
not commonly encountered in daily life. Additionally, many
ofthesestudieslimittheiranalysistothecomponentsofsway
while the base of support remains ﬁxed omitting analysis
of protective steps [11, 16]. Therefore, rather than using
measures that lacked ecological validity, we selected the Pull
Test because of its wide use in clinical neurology practice.
Clinically, the Pull Test became the most widely used tool for
clinical evaluation of postural instability in patients with PD
when it was incorporated into the Uniﬁed Parkinson Disease
Rating Scale (UPDRS) [17] in 1987. However, current
research suggests the Pull Test in isolation is not accurate in
predicting fallers, especially in the ON medication state [5,
18]. Also, the Pull Test has no formal consensus on its exact
execution and low intra- and interrater consistency [5, 19].
Despitetheseconcerns,thePullTestisoneoftheonlyclinical
balance test that examines reactive postural responses and
provides insight into postural reﬂexes without being con-
foundedbyotheraspectsofmobility[7].Inordertoexamine
postural responses, without being corrupted by mobility,
the Pull Test is performed by pulling the subject’s shoulders
posteriorly inducing a protective stepping response. To our
knowledge, no studies have kinematically examined the Pull
Test to explore the temporal and spatial characteristics in
response to interventions such as dopamine replacement.
Ideally, community ambulation and monitoring of fall
risk would provide direct measurement of gait-related
mobility including step counts [20], variability of ambula-
tory activity [21], episodes of instability, and falls. Although
some research groups have demonstrated monitoring within
limited tasks or environments [22, 23], sustained multiday
measurement is not technologically feasible at this time
and is subject to a multitude of confounding inﬂuences
[24]. Because of these concerns, we selected a clinical
measure that is comprised of a set of posturally challenging
gait tasks that a person with PD may encounter during
community mobility (the FGA [25]). Previous research has
suggested that the FGA may have greater ecological validity
to postural challenges during community mobility than
the Pull Test [26–28]. Furthermore, the FGA was selected
because previous research has documented its validity in
people with Parkinson disease [18, 29], vestibular disorders
[25], as well as other neurologically impaired populations
[30]. The FGA was administered in a standardized location
asdescribedintheoriginalpublication[25]andiscomprised
of 10 items each worth a maximum of 3 points for a total
possible score of 30. Higher scores are indicative of more
stability during-speciﬁc balance tasks.
2.3. Procedures. Prior to testing, approval for the study was
obtained from the Institutional Review Board (IRB) at the
University of Utah. After recruitment, the purposes and
procedures of the study were explained and all subjects
signed an IRB approved consent form. After obtaining con-
sent, demographics and disease speciﬁc variables were
obtained from each participant.
All testing was conducted at the Wellness and Rehabil-
itation Clinic and the Motion Capture Core Facility at the
University of Utah, Department of Physical Therapy, and
took place on two separate days.
For both days of testing, the clinically deﬁned OFF
medication condition was induced by having the participant
oﬀ their dopamine-replacement medications for at least
12 hours prior to testing and is consistent with CAPIT
guidelines for OFF medication testing [31]. After completing
OFF medication testing, participants took their medication
and rested for 1 to 1.5 hours and were retested in a clinically
deﬁned ON medication condition.
On the ﬁrst testing day, the motor subsections of the
UPDRSandFGA,duringbothONandOFFmedicationcon-
ditions, were conducted by one physical therapist that had
undergone standardized training on performance of the
UPDRS. Because of the signiﬁcant medication eﬀects, the
tester was not blinded to medication condition. In conjunc-
tion with the UPDRS testing, a modiﬁed Hoehn and Yahr
(H&Y) stage [32] was assigned and a single Pull Test was
performed and rated using the standardized scoring criteria
[17]. Following completion of the UPDRS, participants
performed the FGA.
On the second day, testing was performed in the Motion
Capture Core Facility. This laboratory is equipped with an
eight-camera motion analysis system (Vicon Motion Sys-
tems; Oxford, UK) and two force plates (AMTI; Watertown,
Mass, USA). Prior to participants’ entry into the labora-
tory, a static and dynamic calibration of the system was
performed. Individual anthropometric data were recorded.
Passive reﬂective markers were placed on bony landmarks
utilizing a standardized gait analysis marker set (Plug-
In-Gait, Vicon Motion Systems; Oxford, UK). FollowingParkinson’s Disease 3
subject and system preparation, participants were given an
explanation of the Pull Test prior to the execution of the test
trials [17]. Once the participant gave verbal conﬁrmation
that they understood the test, the participant was placed
into position. The examiner, using the UPDRS testing
description, performed the Pull Test. Participants performed
ﬁvetrialsinboththeONandOFFmedicationcondition.For
all trials, kinetic and kinematic data were collected at 250Hz.
Performance of the Pull Test was characterized using
select spatial and temporal variables rather than just using
the observational criteria as outlined in the UPDRS. To
accomplish this, we segregated out 5 potential temporal
and spatial contributors to abnormal Pull Test performance.
These variables were chosen to speciﬁcally examine temporal
and spatial constructs that have been previously shown to
be aﬀected by PD (reaction time, movement amplitude,
and movement speed) [16]. The ﬁve kinematic dependent
v a r i a b l e sw e r ed e ﬁ n e da sf o l l o w s .
(i) Step reaction time: the time latency (in seconds
[sec]) from the initial examiner induced shoulder
movement until the time of initial foot movement of
the initial stepping limb.
(ii) Step length: the distance (in centimeters [cm]) from
the static sagital plane position of the heel marker of
the initial stepping limb to the sagital plane position
of the heel marker at initial contact of the initial
stepping limb.
(iii) Step average velocity:s t e pl e n g t hd i v i d e db ys t e pt i m e
(in cm/sec). Step time was deﬁned as the time latency
from initial foot movement until the time of foot
contact (in sec) of the initial stepping limb.
(iv) COM displacement: the sagital plane distance (in cm)
from the initial COM position to the COM position
at time of foot contact of the initial stepping limb.
(v) COM average velocity: COM displacement divided by
COM time (in cm/sec). COM time is deﬁned as time
latencyfrominitialCOMmovementuntilthetimeof
foot contact (in sec) of the initial stepping limb.
For each dependent variable, the average of the ﬁrst
three fully measured trials was used as the representative
dependent variable. A fully measured trial consisted of the
participant taking at least one step backwards to regain
balance following the Pull Test and that all markers remained
visible during the trial.
2.4. Data Analysis. All statistical analyses were performed
withSPSS16forMacintosh(SPSSInc.).Descriptivestatistics
wereperformedfordemographicvariables.Theindependent
variable used for analysis of our primary hypotheses was
medication condition (2 levels: ON and OFF medication).
Due to the relatively small sample size and the potential
for nonnormally distributed data, in the primary analyses,
between medication condition diﬀerences were compared
using separate nonparametric tests for dependent samples.
To examine our ﬁndings in more detail, we performed
several post hoc means of analysis. First, between-condition
eﬀect sizes were calculated to compare the magnitude of
eﬀect of the kinematic variables and the FGA. In addition,
we examined the changes of the speciﬁc items on the
FGA in order to gain insight into the locus of eﬀect of
medication on FGA performance. Diﬀerences between the
ON and OFF medication conditions for each FGA item were
compared using separate nonparametric tests for dependent
samples and between-condition eﬀect sizes. A determination
of whether or not an item was dopamine-responsive was
made by examining the statistical signiﬁcance, the within-
medication eﬀect size, and the number of individuals in the
sample who improved on an item when ON medication. A
conservative approach was applied to this decision in that
items were determined to be dopamine-responsive only if
3 criteria were met: (1) there was statistical signiﬁcance
between medication conditions (P<0.005), (2) there was a
large eﬀect size (ES > 0.70), and (3) the majority of individ-
uals tested demonstrated a performance improvement with
dopamine-replacement medication (>7/15).
The experiment wide level of signiﬁcance was set at P<
0.05. However, to control for type I error risk, the overall
alpha level for the tests for diﬀerences was adjusted using
a Bonferroni correction separately within the primary and
post hoc analyses (primary analyses: 0.05/6 comparisons,
thereforeP<0.008wasneededforsigniﬁcanceonindividual
kinematic variables, and the overall FGA; post hoc analyses:
0.05/10, therefore P<0.005 was needed for signiﬁcance on
individual FGA items).
3. Results
Fifteen persons (9 male, 6 female; mean age: 67 ± 13 years)
with PD (disease duration: 7.5 ± 5.0 years) participated in
this study. Their median (range) Hoehn and Yahr rating
and mean (SD) UPDRS (motor subsection) was 2.5 (2–4)
and 13.7 (6.8), respectively, while ON medication and 3.0
(2.5–4) and 27.6 (7.0), respectively, while OFF medication.
Furthermore, 8 of the 15 participants in this study reported
a history of falls.
3.1. Comparison of Reactive Postural Responses during ON
and OFF Medication Conditions. Comparison of the reactive
postural response variables recorded from the Pull Test
revealed no signiﬁcant diﬀerence between ON and OFF
medication conditions. In addition, the eﬀect sizes for
dopamine replacement for all the postural response variables
were small (0.02–0.12) (Table 1, Figures 1 and 2).
3.2. Comparison of Clinical Balance Test Performance during
ON and OFF Medication Conditions. Comparison of the
index scores for the FGA revealed a signiﬁcant higher
score during the ON medication condition (P ≤ 0.008).
Furthermore, the eﬀect size for dopamine replacement on
the FGA score was 1.07 (Table 1, Figure 3). In addition,
post hoc examination revealed that dopamine-replacement-
medication-induced improvements in FGA scores were
focused on a select group of tasks (Table 2).4 Parkinson’s Disease
Table 1: Results of PD group ON and OFF medication (Mean ± SD).
Step reaction
time (sec)
Step length
(cm)
Step avg velocity
(cm/sec)
COM
displacement
(cm)
COM avg velocity
(cm/sec)
Pull Test (UPDRS
motor subsection
item 30)
FGA
ON meds 95%
CI
0.77 ± 0.39 25.94 ± 10.33 62.45 ± 17.11 19.05 ± 6.91 19.42 ± 6.59 0.73 ± 0.46 23.67 ± 4.59∗
0.56–0.99 20.22–31.67 52.98–71.93 15.23–22.88 15.77–23.07 0.48–0.99 21.12–26.21
OFF meds 95%
CI
0.75 ± 0.39 25.72 ± 11.61 63.38 ± 24.05 19.66 ± 7.46 20.20 ± 7.01 1.0 ± 0.53 18.80 ± 4.80
0.53–0.97 19.29–32.15 50.07–76.70 15.53–23.80 16.32–24.09 0.70–1.30 16.14–21.46
Eﬀect size 0.06 0.02 .05 0.09 0.12 0.56 1.07
∗P ≤ 0.008.
(a)
(b)
Figure 1: Visual representation of marker data during ON (a) and
OFF (b) medication testing trials. White lines depict the equality of
step length (Mean (SD): (a) 25.94 (10.33), (b) 25.72 (11.61)).
4. Discussion
Our clinical experience and previous reports in the literature
have suggested that dopamine replacement may have a
diﬀerential eﬀect on reactive postural responses compared
with gait-related mobility. Speciﬁcally, through its reduction
of bradykinesia and rigidity [33, 34], it may improve gait-
related mobility. Despite these improvements, laboratory
studies of reactive and anticipatory postural tasks suggest
that postural coordination is not improved [13, 35]. There-
fore, with improved gait-related mobility and deﬁcient pos-
tural coordination, some individuals may have an increased
risk of falling. This paradox was the basis for this study.
Our results agreed with our hypotheses that dopamine
replacement does not have a signiﬁcant inﬂuence on reactive
postural responses as measured by the temporal and spatial
characteristics of the Pull Test. In addition, as hypoth-
esized, dopamine-replacement medication improved gait-
related mobility as measured by the overall FGA score.
Further investigation of the results from the FGA indicated
that dopamine-replacement medication improved a limited
number of items.
Ultimately, fall events in everyday life are a product of
postural abilities and the frequency of exposure to postural
challenges. The research designs (ON and OFF medication
testing as well as the measures utilized) were intended
to systematically provide an initial controlled examination
of the possibility that dopamine-replacement medications
may improve gait-related mobility without commensurate
improvements in reactive postural responses. As an intial
step in exploring this postural response—mobility paradox,
we found that this is indeed the case. Conceivably, if such
ad i ﬀerential eﬀect persisted during community mobility, it
could lead to increased fall risk and falls in the community
through greater exposure to balance challenges and still
deﬁcient postural responses. Certainly, this proposition
requires further research.
5. A MeasuredView of the PullTest
The validity of the Pull Test as a predictor of falls and
value in clinical balance examinations has been questioned
[18, 36, 37]. Although our results could be seen as support
for this view, we do not interpret our ﬁndings in this way.Parkinson’s Disease 5
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The kinematic characteristics of the Pull Test reported in this
study are consistent with the hypokinetic reactive postural
responses seen in other studies [14, 27]. Few clinical balance
tests examine reactive postural responses as a component
of the motor sign of postural instability. In isolation, such
informationprovidesanarrowviewofpotentialcontributors
to fall risk of persons with PD in the community. However,
in conjunction with other clinical balance tests, the exami-
nation of reactive postural responses may provide clinicians
with a better understanding of postural instability and fall
risk in persons with PD. In addition, concerns regarding
Pull Test reliability may be addressed through the use of the
recently proposed Push and Release Test [37]a sw e l la st h e
BalanceEvaluationSystemsTest(BESTtestandastreamlined
version (the Mini-BEST)) [29, 38].
6. Implications for Rehabilitation
Throughtheanalysisofthevalidityindicesofclinicalbalance
tests, we previously advocated for a battery of tests [39]
and environmentally valid testing [18] in the examination
of fall risk in individuals with PD. Our current ﬁndings add
an additional dimension to this issue. Analysis of reactive
postural responses revealed no consistent medication eﬀect.
Examination of speciﬁc FGA items suggested that tasks with
stable sensory integration demands (e.g., walking on solid
ground with eyes open) were more likely to be dopamine-
responsive. In contrast, the dopamine-nonresponsive items
shared the constraint of ﬂuctuating sensory integration
demands (e.g., gait with horizontal head turns). While this
interpretation is speculative, such ﬁndings suggest that clini-
cians should not blindly accept a composite score or speciﬁc
biomechanical outcome as an indicator of fall risk or as
response to a rehabilitation intervention. Rather, there must
be a critical analysis of the individual task performance in
order to understand the clinical implications of examination
ﬁndings and the potential targets for intervention.6 Parkinson’s Disease
Table 2: FGA item analysis: items were determined to be dopamine responsive if 3 criteria were met: (1) there was statistical signiﬁcance
between medication conditions, (P<0.005) (2) there was a large eﬀect size (ES > 0.70), and (3) the majority of individuals tested
demonstrated a performance improvement with dopamine replacement.
FGA Item Between-medication
condition signiﬁcance level
Between-medication
condition eﬀect size
Number with positive
dopamine-replacement
eﬀect
Dopamine-
responsive
(Yes/No)
(1) Gait on a level surface P<0.002 1.07 9/15 Yes
(2) Change in gait speed P<0.004 1.03 8/15 Yes
(3) Gait with horizontal head turns P<0.017 0.63 5/15 No
(4) Gait with sustained vertical head positions P<0.003 0.85 7/15 No
(5) Gait and pivot turn P<0.017 0.65 7/15 No
(6) Step over obstacle P<0.090 0.31 2/15 No
(7) Gait with narrow base of support P<0.003 0.90 9/15 Yes
(8) Gait with eyes closed P<0.048 0.47 5/15 No
(9) Ambulating backwards P<0.017 0.75 7/15 No
(10) Steps P<0.080 0.32 2/15 No
Despite the fact that postural instability appears to be
a dopamine-resistant motor sign, it does not follow that it
is not amenable to change. There are few studies that have
examined the eﬃcacy of focused rehabilitation interventions
on kinematic and kinetic outcomes [40]. In the few studies
thathaveexaminedsuchoutcomes,therearesuggestionsthat
reactive postural responses or postural sway may improve
with focused training of an adequate dosage [41].
7. Limitations andDirectionsfor Research
Despite their statistical signiﬁcance, these results should
be interpreted with caution. Future research with larger
samples is needed to gain further insight into the beneﬁcial
and potentially detrimental eﬀects of dopamine replace-
ment on postural performance and falls. Furthermore, this
study included only persons currently taking dopamine-
replacement medications, and we did not randomize the
order of the ON and OFF medication conditions. While
such a cohort may reﬂect persons who have progressed to a
moderatedisease severity, persons withmildPD(Hoehnand
Yahr stage 1) and severe PD (Hoehn and Yahr stage 5) did
not participate in this study. Future research should examine
participants with these characteristics as well as persons who
have undergone surgical management of their PD (such as
deep brain stimulation). Lastly, by design, this study used
constrained outcomes, such as the Pull Test and the FGA, as
an initial test of the posture and mobility paradox. Future
studies of postural performance and falls in persons with PD
should attempt to employ validated measures of reactive and
anticipatory balance responses, clinical balance abilities, and
community ambulatory/fall risk monitoring as outcomes.
8. SummaryandClinicalImplications
Our ﬁndings suggest that dopamine-replacement medi-
cations alone may improve gait-related mobility without
commensurate improvements in reactive postural responses
and therefore could result in iatrogenic increases in fall risk.
Rehabilitationprovidersshouldbeawareofthelimitationsof
dopamine-replacement treatment and implement interven-
tions intended to improve postural responses.
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